Trial Profile
Two-Arm Open-Labeled Trial of HPV-E6-Specific TCR-T Cells With or Without Anti-PD1 Auto-secreted Element in the Treatment of HPV-Positive Head and Neck Carcinoma or Cervical Cancer
Status:
Not stated
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs T cell receptor therapy-TCRCure Biotech (Primary)
- Indications Carcinoma; Cervical cancer; Head and neck cancer
- Focus Adverse reactions
- 02 Sep 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2019).
- 29 Apr 2019 Status changed from recruiting to not stated.
- 29 Apr 2019 Planned number of patients changed from 9 to 20.